Physician profile
Paul Modafferi
NPI 1760880082
$12,087.72
in general payments reported to CMS, 2019-2025
37 companies · $2,443 in 2025
The $2,443 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,831 · 2022: $2,446 · 2023: $2,642 · 2024: $2,726 · 2025: $2,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,811.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,587.84 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,339.43 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,244.44 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $1,078.04 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $977.70 | 2022-2025 | |
| Pfizer INC. | $954.10 | 2022-2025 | |
| Abbvie INC. | $831.95 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.07 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $414.12 | 2021-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $389.45 | 2021-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Astellas Pharma US INC | $340.29 | 2021-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $309.99 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $234.79 | 2024-2025 | Voquezna |
| Abbott Laboratories | $215.51 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $192.67 | 2021-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $146.70 | 2021-2023 | Belsomra, Steglatro |
| Exact Sciences Corporation | $144.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $139.29 | 2022-2025 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $138.05 | 2021-2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Biohaven Pharmaceuticals, INC. | $116.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $114.04 | 2021-2024 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $113.67 | 2022 | |
| Idorsia Pharmaceuticals US INC | $93.09 | 2022-2024 | Quviviq |
| Ucb, INC. | $89.20 | 2025 | Bimzelx |
| Corcept Therapeutics | $80.93 | 2022-2023 | Korlym |
| Kowa Pharmaceuticals America, INC. | $63.89 | 2021 | |
| Amarin Pharma, INC. | $61.70 | 2021 | |
| Sumitomo Pharma America, INC. | $59.95 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $36.03 | 2023-2025 | Nexletol |
| Ibsa Pharma INC. | $33.51 | 2024 | Licart, Tirosint, Flector |
| Medtronic, INC. | $25.78 | 2025 | Inceptiv |
| Teva Pharmaceuticals USA, INC. | $22.91 | 2021 | |
| Biogen, INC. | $19.89 | 2021 | |
| Inogen, INC. | $17.28 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.67 | 2025 | Caplyta |
| Azurity Pharmaceuticals, INC. | $14.99 | 2025 | Katerzia |
| Jazz Pharmaceuticals INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Modafferi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.